



(51) International Patent Classification:

C07C 271/18 (2006.01) A61K 31/195 (2006.01)
 C07C 271/24 (2006.01) A61K 31/215 (2006.01)
 C07C 229/50 (2006.01) A61P 25/18 (2006.01)
 C07C 237/04 (2006.01) A61P 29/00 (2006.01)
 A61K 31/16 (2006.01) C07C 323/25 (2006.01)
 A61K 31/325 (2006.01)

(21) International Application Number:

PCT/US2013/023529

(22) International Filing Date:

29 January 2013 (29.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12382038.3 1 February 2012 (01.02.2012) EP
 61/619,139 2 April 2012 (02.04.2012) US

(71) Applicant: ELI LILLY AND COMPANY [US/US];
Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: BAKER, Stephen, Richard; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, IN 46206-6288 (US). BEADLE, Christopher David; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, IN 46206-6288 (US). CLARK, Barry Peter; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, IN 46206-6288 (US). MONN, James Allen; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, IN 46206-6288 (US). PRIETO, Lourdes; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).

(74) Agents: HOSTETTLER, Danica et al.; Eli Lilly and Company, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: MGLU 2/3 AGONISTS



(I)

(57) Abstract: The present invention provides novel mGlu2/3 agonists of formula (I) useful in the treatment of neurological or psychiatric disorders.